Søgeresultater - Sumana Devata

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial

    Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial af Asra Ahmed, Samuel A. Merrill, Fares Alsawah, Paula Bockenstedt, Erica Campagnaro, Sumana Devata, Scott D. Gitlin, Mark Kaminski, Alice Cusick, Tycel Phillips, Suman L. Sood, Moshe Talpaz, Albert Quiery, Philip S. Boonstra, Ryan A. Wilcox

    Udgivet 2019
    Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  2. 2
    Double Step-up Dosing (2SUD) Regimen Mitigates Severe Icans and CRS While Maintaining High Efficacy in Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL) Treated with AZD0486, a Novel CD19xCD3 T-Cell Engager (TCE): Updated Safety and Efficacy Data from the Ongoing First-in-Human (FIH) Phase 1 Trial

    Double Step-up Dosing (2SUD) Regimen Mitigates Severe Icans and CRS While Maintaining High Efficacy in Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL) Tre... af Sameh Gaballa, Ranjit Nair, Ryan Jacobs, Sumana Devata, Seok‐Goo Cho, Don A. Stevens, Dok Hyun Yoon, Nirav N. Shah, Denise Brennan, Jason Law, Robert Chen, David Sermer, Robin Lesley, Ben Buelow, Alessandra Forcina, Jing‐Zhou Hou

    Udgivet 2023
    Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  3. 3
    Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

    Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma af Auris Huen, Bradley M. Haverkos, Jasmine M. Zain, Radhakrishnan Ramchandren, Mary Jo Lechowicz, Sumana Devata, Neil J. Korman, Lauren Pinter‐Brown, Yasuhiro Oki, Prajak J. Barde, Ajit Nair, Kasi V. Routhu, Srikant Viswanadha, Swaroop Vakkalanka, Swaminathan P. Iyer

    Udgivet 2020
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  4. 4
    A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

    A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma af Nancy L. Bartlett, Alex F. Herrera, Eva Domingo‐Domènech, Amitkumar Mehta, Andres Forero‐Torres, Ramón García‐Sánz, Philippe Armand, Sumana Devata, Antonia Rodríguez Izquierdo, Izidore S. Lossos, Craig B. Reeder, Taimur Sher, Robert Chen, Sylvia E. Schwarz, Leila Alland, András Strassz, Kim Prier, Cassandra Choe-Juliak, Stephen M. Ansell

    Udgivet 2020
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:

Søgeredskaber: